Wellesley, Mass.

Pandemic infections are causing concern for healthcare providers and organizations globally as pandemic infections such as human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), hepatitis B and C, and tuberculosis continue to expand by geographic area as well as virulence. Additionally, antibiotic-resistant infections have made providers and manufacturers aware of serious deficiencies in current pharmaceutical products. HIV/AIDS diagnostic and pharmaceutical products will not see as dramatic annual growth rates as they have in the past, but the market will continue to expand at a healthy pace as the result of sales of combination therapies. Combination products (i.e., those used for highly active antiretroviral therapy [HAART]) are taking market shares away from single-chemical agents, and this trend will continue throughout the forecast period. Drug resistance is a real problem in HIV/AIDS treatments as well; therefore, new classes of products will find waiting markets in the growing number of patients who are becoming resistant to existing drugs. Multidrug-resistant strains of tuberculosis (TB), HIV/AIDS, Staphylococcus aureus, enterococcus, and Clostridium difficile have pushed manufacturers to develop new diagnostic and pharmaceutical products to meet pressing demands. Demand for viral pandemic diagnostic and pharmaceutical products will continue to expand at a five-year compound annual growth rate (CAGR) of 9.5% from 2012 through 2017, while the combined global market for viral, bacterial, and parasitic diagnostic and pharmaceutical products will grow at a CAGR of 9.3%. The greatest market share in 2017 will be held by countries in the Asian region. Global Markets and Technologies for Pandemic Control (PHM042B) outlines the available preventive and diagnostic products used to combat current and future pandemic infections and projects markets for these products. Forecasts are provided for the diagnostic and pharmaceutical markets for products to treat HIV/AIDS, hepatitis B and C, malaria, and tuberculosis. Forecasts and trends are gleaned from industry sources as well as from a considered assessment of emerging products and technologies. The causes, the extent of impact, and strategies to monitor, treat and prevent resistant diseases are assessed. The mechanisms by which drugs function to combat resistant microbes are described. Drugs that show promise of long-term activity (i.e., low likelihood of resistance) and their effect on the market are assessed.